<?xml version='1.0' encoding='utf-8'?>
<document id="28584788"><sentence text="Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis." /><sentence text="The emergence of drug-resistant tuberculosis (TB) is a growing problem worldwide" /><sentence text=" The lack of safe and effective drugs, together with the frequent development of adverse drug reactions can result in worse outcomes" /><sentence text=" Therefore, new TB drugs able to bolster the current TB treatment regimen are urgently required" /><sentence text=" Novel drugs that are effective and safe against Mycobacterium tuberculosis are required to reduce the number of drugs and the duration of treatment in both drug-susceptible TB and multi-drug-resistant (MDR)-TB" /><sentence text=" This review covers promising novel TB drugs and regimens that are currently under development" /><sentence text=" Bedaquiline and delamanid are the most promising novel drugs for the treatment of MDR-TB, each having a high efficacy and tolerability"><entity charOffset="1-12" id="DDI-PubMed.28584788.s7.e0" text="Bedaquiline" /><entity charOffset="17-26" id="DDI-PubMed.28584788.s7.e1" text="delamanid" /><pair ddi="false" e1="DDI-PubMed.28584788.s7.e0" e2="DDI-PubMed.28584788.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28584788.s7.e0" e2="DDI-PubMed.28584788.s7.e1" /></sentence><sentence text=" However, the best regimen for achieving better outcomes and reducing adverse drug reactions remains yet to be determined, with safety concerns regarding cardiac events due to QT prolongation still to be addressed" /><sentence text=" Pretomanid is a novel drug that potentially shortens the duration of treatment in both drug-susceptible and drug-resistant TB" /><sentence text=" Many regimens consisting of injection free drugs with shorter treatment duration compared to the conventional treatment are now undergoing clinical trials" /><sentence text=" Therefore a simple and short treatment with higher efficacy, and lesser adverse drug reactions and drug-drug interaction is expected for patients with MDR-TB" /><sentence text="" /></document>